4.65
+0.46(+10.98%)
Currency In USD
| Previous Close | 4.19 |
| Open | 4.15 |
| Day High | 4.73 |
| Day Low | 4.09 |
| 52-Week High | 10.88 |
| 52-Week Low | 2.9 |
| Volume | 4.26M |
| Average Volume | 2.77M |
| Market Cap | 410.4M |
| PE | -4.35 |
| EPS | -1.07 |
| Moving Average 50 Days | 3.93 |
| Moving Average 200 Days | 4.8 |
| Change | 0.46 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $34.91 as of November 19, 2025 at a share price of $4.65. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $485.89 as of November 19, 2025 at a share price of $4.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 11, 2025 1:51 PM GMT
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, in
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 07, 2025 1:05 PM GMT
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
GlobeNewswire Inc.
Nov 03, 2025 12:30 PM GMT
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025